EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the efficacy and safety of photodynamic therapy and platelet-rich plasma in the treatment of androgenic alopecia: a randomized prospective pilot study

Ekaterina A. Antonova, Vladimir B. Pinegin, Farah Bedoui

Russian Journal of Skin and Venereal Diseases · 05.09.2026 · 29 (5) · 615-624

DOI: 10.17816/dv708079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Russian Journal of Skin and Venereal Diseases, online erschienen am 05.09.2026. Verfasst von Ekaterina A. Antonova und 2 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Androgenetic alopecia is a common problem in dermatological practice. The pathogenesis of the disease is driven by the effect of dihydrotestosterone on hair follicles, which triggers progressive shortening of the anagen phase and a decrease in hair diameter. Despite the availability of numerous approved treatments for this condition, the clinical response is not always sufficient. Therefore, physicians need to develop new treatment regimens for androgenetic alopecia that will improve treatment outcomes. AIM: To evaluate the effect of photodynamic therapy on the course of androgenetic alopecia as monotherapy and in combination with platelet-rich plasma. METHODS: An open-label, randomized, prospective, pilot study was conducted. 10 patients (5 men and 5 women) diagnosed with androgenetic alopecia were divided into 2 groups. Patients in group 1 received red-spectrum photodynamic therapy with hypericin (wavelength, 670 nm; power, 17 mW/cm²; procedure time, 15 minutes; course of 10 procedures once a week). Patients in group 2 received photodynamic therapy with similar parameters and platelet-rich plasma injections (course of 5 procedures once every 2 weeks). The primary outcomes were safety and phototrichogram parameters (changes in hair density, percentage of anagen hairs, and hair growth rate). RESULTS: Based on the treatment results of 10 patients, no serious adverse effects were recorded. One patient reported transient folliculitis during the first 3 days after plasma therapy. No adverse effects were recorded due to photodynamic therapy. In both groups, statistically significant positive changes were observed in hair density parameters in the parietal zone (group 1: p=0.039; group 2: p=0.005) and in the percentage of anagen hairs. A comparative analysis of delta changes showed a statistically significant increase in hair growth rate in zone 1 (parietal) in the combination treatment group compared with photodynamic monotherapy (p=0.045). No significant differences were found between the groups for other parameters, likely due to the small sample size. CONCLUSION: Combination treatment is safe and demonstrates a tendency toward greater efficacy compared with monotherapy. The results confirm the potential of photodynamic therapy in treating patients with androgenetic alopecia and justify further full-scale clinical trials.

Zitieren

APA

Antonova, E. A., Pinegin, V. B., & Bedoui, F. (2026). Evaluation of the efficacy and safety of photodynamic therapy and platelet-rich plasma in the treatment of androgenic alopecia: a randomized prospective pilot study. Russian Journal of Skin and Venereal Diseases, 29(5), 615-624. https://doi.org/10.17816/dv708079

Vancouver

Antonova EA, Pinegin VB, Bedoui F. Evaluation of the efficacy and safety of photodynamic therapy and platelet-rich plasma in the treatment of androgenic alopecia: a randomized prospective pilot study. Russian Journal of Skin and Venereal Diseases. 2026;29(5):615-624. doi:10.17816/dv708079

BibTeX
@article{Antonova2026,
  author = {Antonova, Ekaterina A. and Pinegin, Vladimir B. and Bedoui, Farah},
  title = {Evaluation of the efficacy and safety of photodynamic therapy and platelet-rich plasma in the treatment of androgenic alopecia: a randomized prospective pilot study},
  journal = {Russian Journal of Skin and Venereal Diseases},
  year = {2026},
  volume = {29},
  number = {5},
  pages = {615--624},
  doi = {10.17816/dv708079}
}
Kostenlos starten →